ArticleActa neuropathologica2021
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Philipp Sievers et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it